The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs BMS 986195 (Primary) ; Ethinylestradiol/norethisterone
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 15 Feb 2018 Status changed from active, no longer recruiting to completed.
- 16 Jan 2018 Planned End Date changed from 26 Dec 2017 to 31 Jan 2018.
- 16 Jan 2018 Planned primary completion date changed from 25 Dec 2017 to 30 Jan 2018.